Trial Profile
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs H3B 8800 (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Acronyms Encore-MDS
- Sponsors H3 Biomedicine
- 13 Feb 2024 According to a Roivant Sciences media release, the company has discontinued development of H3B-8800 (RVT-2001) after an interim data analysis from this trial.
- 13 Feb 2024 Status changed from active, no longer recruiting to discontinued, According to a Roivant Sciences media release.
- 13 Nov 2023 According to a Roivant Sciences media release, Hemavant plans to announce data from the ongoing open-label Phase 1/2 trial evaluating RVT-2001 for the treatment of transfusion-dependent anemia in lower-risk myelodysplastic syndromes (MDS) patients in the first quarter of calendar year 2024.